Understanding how CTB-INS modulates IDO1 activity in human dendritic cells will facilitate the improvement of vaccine efficacy and safety, moving this effective immunosuppressive strategy closer to clinical applications for prevention of T1D. The gene discussed is INS; the disease is type 1 diabetes mellitus.